Microsponge Drug Platform for Methotrexate in Rheumatoid Arthritis
Author Information
Author(s): Noemi Fiaschini, Patrizia Nadia Hanieh, Daniela Ariaudo, Rita Cimino, Carlo Abbate, Elena Romano, Francesca Cavalieri, Mariano Venanzi, Valeria Palumbo, Manuel Scimeca, Roberta Bernardini, Maurizio Mattei, Alberto Migliore, Antonio Rinaldi
Primary Institution: University of Rome Tor Vergata
Hypothesis
Can a novel nanotechnological slow-release drug delivery platform based on hyaluronic acid Microsponge enhance methotrexate administration in rheumatoid arthritis therapy?
Conclusion
The Microsponge drug delivery platform significantly improves the therapeutic efficacy of methotrexate in rheumatoid arthritis by enabling sustained slow release, thus enhancing treatment outcomes and minimizing side effects.
Supporting Evidence
- The MSP achieved a high methotrexate loading efficiency and a slow release profile sustained for over a month.
- Administration of MTX-loaded MSP nearly doubled the therapeutic efficacy compared to sole MTX.
- The study was replicated twice to confirm the improvement in performance and safety profile of the MSP.
- MTX release from the MSP showed a very limited burst release followed by sustained release.
- The absence of endotoxins in the formulations ensures their safety for injection.
Takeaway
Researchers created a special sponge-like system to slowly release a medicine called methotrexate for people with arthritis, which helps them feel better without as many side effects.
Methodology
The study involved synthesizing hyaluronic acid-based microsponge particles, loading them with methotrexate, and testing their release profile and efficacy in a preclinical rat model of rheumatoid arthritis.
Potential Biases
Potential bias may arise from the preclinical nature of the study and the specific animal model used.
Limitations
The study was conducted in a preclinical model, and further clinical trials are needed to confirm the findings in humans.
Participant Demographics
34 female and male Wistar rats aged 9 and 11 weeks were used in the study.
Statistical Information
P-Value
<0.0001
Confidence Interval
95%
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website